A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma
- 1 October 2005
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 50 (1) , 75-82
- https://doi.org/10.1016/j.lungcan.2005.05.007
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Surgical management of malignant pleural mesothelioma: a systematic review and evidence summaryLung Cancer, 2005
- Statistical Validation of the EORTC Prognostic Model for Malignant Pleural Mesothelioma Based on Three Consecutive Phase II TrialsJournal of Clinical Oncology, 2005
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- Surgical Treatment of Malignant Pleural Mesothelioma*Chest, 2003
- Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysisLung Cancer, 2002
- Factors Predictive of Survival Among 337 Patients With Mesothelioma Treated Between 1984 and 1994 by the Cancer and Leukemia Group BChest, 1998
- A Review of Chemotherapy Trials for Malignant MesotheliomaChest, 1998
- Surgically debulked malignant pleural mesothelioma: Results and prognostic factorsAnnals of Surgical Oncology, 1997
- Chemotherapy in malignant pleural mesothelioma. A review.Journal of Clinical Oncology, 1996
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989